At Invea, we use a proprietary AI platform to expedite the discovery and development of precision medicines for gastrointestinal and hepatobiliary disorders impacted by dysregulation of the GBA. We have focused our attention on applying AI and machine learning as a force multiplier to aid in target and drug discovery, disease indication prioritization, through to successful clinical development and approval.